Back to dashboard
CommercialAdministrativeLow impact

08.02.11b, Nadofaragene Firadenovec-vncg (Adstiladrin®)

Independence Blue Cross·Oncology, Urology·Pharmacy
Effective date
Sep 3, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

This is a commercial policy reissue for Nadofaragene Firadenovec-vncg (Adstiladrin®), a pharmacy/drug policy. The policy appears to be a routine reissue with no content changes indicated, maintaining existing coverage or billing requirements for this specialized oncology medication.

Action Required

Action needed
By September 3, 2025: Billing team should review the full policy details at the source URL to confirm any changes to coverage, prior authorization, or billing requirements for Nadofaragene Firadenovec-vncg (Adstiladrin®). Update any relevant billing protocols if changes are identified in the complete policy text.

Related policy hubs